

**Section Head**  
Dr Silvia Franceschi

## SECTION OF INFECTIONS (INF)

THE NEW SECTION OF INFECTIONS (INF) COMPRISES TWO GROUPS: THE INFECTIONS AND CANCER EPIDEMIOLOGY GROUP (ICE) AND THE INFECTIONS AND CANCER BIOLOGY GROUP (ICB). THE REORGANISATION OF THE SCIENTIFIC STRUCTURE OF IARC HAS THEREFORE LEFT THE SITUATION OF ICE AND ICB UNCHANGED, AS THEY WERE TOGETHER IN THE EPIDEMIOLOGY AND BIOLOGY CLUSTER BEFORE 2009.

Persistent infection with viruses, bacteria and parasites account for approximately 20% of the cancer burden worldwide, with less developed countries being the hardest hit. Infections also represent, or might represent in the future, some of the most preventable cancer causes through immunisation or early detection. Table 1 summarises the infectious agents and the different aspects of the infection/cancer relationship currently under study in INF.

Not all of the topics listed in Table 1 are covered by both Groups. ICB, for instance, is focused on HPV to an even greater extent than is ICE, although it also works on EBV and Merkel cell polyomavirus. Although ICE has never performed large epidemiological studies of non-melanomatous skin cancer, it has collaborated very closely with ICB on the association between cutaneous HPV and squamous cell carcinoma of the conjunctiva.

ICE is more active than ICB in the study of other cancer-associated infections that have either been present in the IARC portfolio for years (*Helicobacter*), or were brought to IARC by the present ICE Group Head (e.g., HIV and HCV). In particular, ICE is a world leader in the study of cancer excess among HIV-positive people. For consistency, some of the long-duration population-based studies previously established in ICE continued with the same extra-mural laboratories they started with. Similarly, the attractiveness of the ICB laboratory has successfully led to extra-

mural collaborations with distinguished epidemiologists and clinicians.

With respect to aspects under study, some are exclusive to ICB (e.g., transformation mechanisms) or ICE (worldwide distribution and trends of cancer-associated infections). Collaborations on other relevant aspects (the role of innate and acquired immunity, the impact of different HPV variants) are becoming possible along with the increasing availability at ICB of tests suitable for large-scale application.

Regardless of the infectious agent or the aspect under study, one of the great assets of INF is the collaboration on methodological issues. It has become routine for ICB to provide advice to ICE regarding decisions on biological protocol

aspects, and for ICE to provide statistical assistance to ICB in its protocols and publications.

Additional collaborations are ongoing with other Sections, notably the Sections of Early Detection and Prevention (EDP), Nutrition and Metabolism (NME), Genetics (GEN), Environment (ENV), Molecular Pathology (MPA) and Mechanisms of Carcinogenesis (MCA).

The over 100 publications produced by INF in 2008–2009 provide good evidence of the high productivity and width of topics and international collaborations entailed in projects coordinated by INF.




**Table 1. Section of Infections Studies**

*Aspects under study*

- Worldwide distribution and trends over time of infections associated with cancer
- Range of tumours associated with infection and strength of the association
- Transformation mechanisms
- Meaning of viral variants
- Role of innate and acquired immunity
- New virological and bacteriological tests for epidemiological studies

*Agents included*

- Mucosal and cutaneous human papillomavirus (HPV) types
- HIV, in combination with other viruses associated with cancer
- *Helicobacter* species
- Hepatitis B and C virus (HBV/HCV)
- Epstein Barr virus (EBV)
- Merkel cell polyomavirus



# INFECTIONS AND CANCER BIOLOGY GROUP (ICB)

## Group Head

Dr Massimo Tommasino

## Scientists

Dr Rosita Accardi

Dr Tarik Gheit

Dr Bakary Sylla

## Technical Assistant

Ms Anne-Marie Aguelon (until November 2009)

## Secretary

Ms Annick Rivoire

## Visiting scientists and postdoctoral fellows

Dr Francisco Aguayo Gonzalez (October 2009-November 2009)

Dr Mojgan Bandehpour (October 2009-November 2009)

Dr Michele Galluccio (November 2008-March 2009)

Dr Raffaella Ghittoni (from March 2009)

Dr Uzma Hasan (until December 2009)

Dr Bahar Jafari (October 2009-November 2009)

Dr Valentina Lupato (August 2009-September 2009)

Dr Ruchi Shukla (May 2007-November 2009)

Dr Jiping Yue (July 2007-July 2010)

Dr Claudia Zannetti (January 2007-January 2010)

## Students

Ms Jeanneke Arends (September 2008-December 2008)

Mr Sven Bergner (April 2008-July 2008)

Ms Sybil Bertrand (May 2008-July 2008)

Ms Chiara Camillo (May 2008-June 2008)

Ms Valeria Caneparo (September 2008-October 2008)

Ms Iris Cornet (October 2008-September 2009)

Ms Marion Creveaux (May 2008-September 2008)

Ms Ikbal Fathallah (until January 2010)

Ms Hanna Johansson (February 2008-June 2008)

Ms Marine Malfroy (September 2008-February 2009)

Ms Rocchina Miglionico (October 2008-December 2008)

Ms Caroline Odenwald (September 2009-December 2009)

Ms Peggy Parroche (February 2008-February 2010)

Ms Marion Peyressatre (May 2009-September 2009)

Ms Alice Poli (February 2008-November 2008)

Ms Hanna Rövenich (June 2008-August 2008)

Ms Rosa Rubino (January 2009-September 2009)

Mr Jean-Baptiste Ruer (March 2008-April 2008)

Mr Djamel Saidj (January 2009-March 2009 & August 2009-July 2010)

Dr Mariafrancesca Scalise (May 2009-May 2010)

Mr Sinto Sebastian (until March 2008)

Ms Maha Siouda (January 2009-March 2009 & August 2009-July 2010)

Ms Giuliana Ventriglia (May 2009-July 2009)

IT IS WELL ESTABLISHED THAT APPROXIMATELY 20% OF HUMAN CANCERS WORLDWIDE ARE ASSOCIATED WITH INFECTIOUS AGENTS. IN ADDITION, NEW EVIDENCE SUPPORTS THE INVOLVEMENT OF ADDITIONAL INFECTIOUS AGENTS IN HUMAN CARCINOGENESIS, WHICH MAY ADD TO THIS TOTAL. A SUB-GROUP OF HPV TYPES THAT INFECT THE SKIN ARE SUSPECTED TO BE INVOLVED, TOGETHER WITH ULTRAVIOLET RADIATION, IN THE DEVELOPMENT OF NON-MELANOMA SKIN CANCER (NMSC). IN ADDITION, A RECENTLY-DISCOVERED HUMAN POLYOMAVIRUS, MERKEL CELL POLYOMAVIRUS (MCPyV), IS ASSOCIATED WITH A RARE TUMOUR, MERKEL CELL SARCOMA.

The main goal of our Group is to establish a causal role of specific infectious agents in human cancer. Two complementary strategies are currently followed: (i) Functional studies to characterise the biological properties of specific infectious agents using *in vitro* and *in vivo* model systems; and (ii) Epidemiological studies to determine the presence of specific infectious agents in benign and malignant human lesions.

The rationale of our functional studies is based on the fact that viruses directly associated with human cancers have developed several mechanisms to efficiently evade immune surveillance and promote cellular transformation. Therefore, studies in the Group aim to characterise the ability of viruses to de-regulate cellular pathways involved in the immune response and cellular transformation in order to predict their oncogenic potential.

Regarding the epidemiological studies, we have generated novel human papillomavirus (HPV) detection assays with high throughput, sensitivity and specificity. Validation studies have shown that our assays significantly increased the HPV DNA detection rate, especially in multiple infections, in comparison to other well-validated and widely-used HPV detection methods. The development of these novel detection assays allowed us to initiate and complete several epidemiological studies.

Future plans of the Group include (i) extension of the functional studies to emerging oncogenic viruses, e.g. human Merkel cell polyomavirus and related viruses; (ii) developing novel detection assays for additional infectious agents; and (iii) expanding the epidemiological studies in collaboration with other groups from IARC and other institutes, including institutes from low-resource countries.

### CUTANEOUS HPV TYPES

The skin-tropic HPV types from the genus beta of the HPV phylogenetic tree, also known as Epidermodysplasia verruciformis (EV) HPV types, are strongly suspected to be involved in NMSC. However, their direct role in human carcinogenesis is not yet fully proven. In addition, it is not yet known whether, as has been observed with mucosal HPV types, beta HPVs may be sub-grouped into low- and high-risk HPV types. To address these questions, we have initiated the characterisation of the biological properties of the main oncoproteins, E6 and E7, from several beta HPV types. Several experimental models have been used, ranging from primary keratinocytes to transgenic mice.

Our data show that certain beta HPV types (i.e. HPV24, 38 and 49) display transforming activities in comparison to other beta HPV types (i.e. HPV14, 22, 23 and 36), supporting the existence of low- and high-risk HPV types (\*Gabet *et al.*, 2008; \*Bouvard *et al.*, ongoing study). Studies on HPV38 have resulted in the identification of a novel viral mechanism of inactivation of p53. Unlike HPV16, HPV38 does not induce p53 degradation but rather promotes accumulation of a potent inhibitor of p53 transcriptional functions, *\_Np73\_* (\*Accardi *et al.*, 2006). HPV38 E6 and E7 expression in the skin of transgenic mice using K10 promoter induced *\_Np73\_* accumulation, cellular proliferation, hyperplasia and dysplasia in the epidermis (\*Dong *et al.*, 2005; \*Accardi *et al.*, 2006; \*Dong *et al.*, 2008). In conclusion, our functional studies support the role of certain beta HPV types in human carcinogenesis.

### MUCOSAL HPV TYPES AND TOLL-LIKE RECEPTOR SIGNALLING

Establishment of a chronic infection is a key event for virus-induced carcinogenesis. Several prospective studies, in which


HPV-positive women have been followed-up for many years, have shown that HPV16 is able to persist much longer in the host than the other mucosal high-risk HPV types. Thus, the high carcinogenicity of HPV16 may be explained by its greater efficiency than the other mucosal high-risk HPV types in evading the immune system. We observed that the expression of a key player in innate immunity, Toll-like receptor 9 (TLR9), which senses the double-stranded viral DNA, is strongly down-regulated by HPV16 E6 and E7 oncoproteins in several *in vitro* experimental models (\*Hasan *et al.*, 2007). Accordingly, immunohistochemical analyses revealed weak TLR9 expression in HPV-positive malignant cervical lesions, while strong TLR9 staining was detected in normal cervical tissues (\*Hasan *et al.*, 2007; ongoing studies). E6 and E7 from other mucosal high-risk HPV types, including HPV18, are less efficient than E6 and E7 from HPV16 in down-regulating TLR9 expression, while the mucosal low-risk HPV6 E6 and E7 do not interfere at all with TLR9 transcription. Thus, the ability of the different HPV types to down-regulate TLR9 expression appears to correlate with their ability to persist.

Based on these data, we have extended our studies to cutaneous beta HPV types and other cancer-associated viruses to target the TLR9 signalling pathway.

### PREVALENCE OF HPV INFECTIONS FROM DIFFERENT ANATOMICAL SITES IN HUMAN SPECIMENS

We have developed a novel assay for the detection of three different groups of HPV, namely (i) mucosal high-risk HPV types (n=19), (ii) mucosal low-risk HPV types (n=18) and (iii) beta and gamma cutaneous HPV types (n=31) (\*Gheit *et al.*, 2006; Gheit *et al.*, 2007; Gheit *et al.*, ongoing study). Due to the high sensitivity and versatility of our HPV detection assay, we were able to perform several epidemiological studies to evaluate the ability of HPV types (i)

to infect a specific anatomical site and/or (ii) to promote carcinogenesis (\*Dai *et al.*, 2007; \*Cazzaniga *et al.*, 2008; \*Rollison *et al.*, 2008). Our data did not provide evidence for the role of the high-risk mucosal HPV types in breast carcinogenesis, but they do suggest a possible involvement of these viruses in a small percentage of oesophageal cancers. In addition, some of the cancer case studies aimed at determining the prevalence of specific mucosal high-risk HPV types in populations that have not yet been analysed (\*Gheit *et al.*, 2009; \*Sideri *et al.*, 2009).



**Figure 1. TLR9 is downregulated in HPV16-positive cervical cancers.**

Sections of normal and tumoral cervical tissues were stained by immuno-histochemistry for pan keratin or TLR9. No TLR9 expression was detected in cervical cancer of two different donors (HPV16a+ and HPV16b+).

**The ICB Group is grateful to the following for their collaboration in its projects:**

- Christophe Caux, Centre Léon-Bérard, Lyon, France
- Massimiliano Cazzaniga, Fausto Chiesa, Mario Sideri and Umberto Veronesi, European Institute of Oncology, Milan, Italy
- Christine Clavel and Philippe Birembaut, Hôpital de la Maison Blanche, Reims, France
- Charles Dumontet, Hôpital Edouard Herriot, Lyon, France
- Lutz Gissmann, DKFZ, Heidelberg, Germany
- Thomas Iftner, University of Tübingen, Germany
- Susanne Krüger Kjær, Institute of Cancer Epidemiology, Copenhagen, Denmark
- Evelyne Manet, Ecole Normale Supérieure, Lyon, France
- Jacqueline Marvel, Immunité, INSERM U851 Lyon, France
- Michael Pawlita, DKFZ, Heidelberg, Germany
- Dana Rollison, Lee Moffitt Cancer Center, Tampa, FL, USA
- Levana Sherman, Sackler School of Medicine, Tel Aviv, Israel
- Ingeborg Zehbe, Regional Cancer Care, Thunder Bay, Canada
- Fabien Zoulim, INSERM U871, Lyon, France

## REFERENCES

- \*Accardi R, Dong W, Smet A, Cui R, Hautefeuille A, Gabet AS, Sylla BS, Gissmann L, Hainaut P, Tommasino M (2006). Skin human papillomavirus type 38 alters p53 functions via accumulation of  $\text{p}73$ . *EMBO Rep.*, 7: 334-40.
- \*Cazzaniga M, Gheit T, Casadio C, Khan N, Macis D, Valenti F, Miller MJ, Sylla BS, Akiba S, Bonanni B, Decensi A, Veronesi U, Tommasino M (2009). Analysis of the presence of cutaneous and mucosal papillomavirus types in ductal lavage fluid, milk and colostrum to evaluate its role in breast carcinogenesis. *Breast Cancer Res. Treat.*, 114:599-605.
- \*Dai M, Zhang WD, Clifford G, Gheit T, He BC, Michael K, Waterboer T, Hainaut P and Tommasino M, Franceschi S (2007). Human papillomavirus infection among 100 oesophageal cancer cases in the People's Republic of China. *Int. J. Cancer*, 121: 1396-8.
- \*Dong W, Klotz U, Accardi R, Caldeira S, Tong WM, Wang ZQ, Jansen L, Dürst M, Sylla BS, Gissmann L, Tommasino M (2005). Skin hyperproliferation and susceptibility to chemical carcinogenesis in transgenic mice expressing E6 and E7 of human papillomavirus type 38. *J. Virol.*, 79: 14899-908.
- \*Dong W, Arpin C, Accardi R, Gissmann L, Sylla BS, Marvel J and Tommasino M (2008). Loss of p53 or p73 in human papillomavirus type 38 E6 and E7 transgenic mice partially restores the UV-activated cell cycle checkpoints. *Oncogene*, 27: 2923-8.
- \*Gabet AS, Accardi R, Bellopede A, Popp S, Boukamp P, Sylla BS, Londoño-Vallejo JA, Tommasino M (2008). Impairment of the telomere/telomerase system and genomic instability are associated with keratinocyte immortalization induced by the skin Human Papillomavirus type 38. *FASEB J.*, 22: 622-32.
- \*Gheit T, Landi S, Gemignani F, Snijders PJF, Vaccarella S, Franceschi S, Canzian F, Tommasino M (2006). Development of a sensitive and specific multiplex PCR method combined with DNA microarray to detect high-risk mucosal human papillomavirus types. *J. Clin. Microbiol.*, 44: 2025-31.
- \*Gheit T, Billoud G, de Koning MNC, Gemignani F, Forslund O, Sylla BS, Vaccarella S, Franceschi S, Landi S, Quint WGV, Canzian F, Tommasino M (2007). Development of a sensitive and specific multiplex PCR method combined with DNA microarray primer extension to detect beta-papillomavirus types. *J. Clin. Microbiol.*, 45: 2537-44.
- \*Gheit T, Vaccarella S, Schmitt M, Pawlita M, Franceschi S, Sankaranarayanan R, Sylla BS, Tommasino M, Gangane N (2009). Prevalence of human papillomavirus types in cervical and oral cancers in central India. *Vaccine*, 27: 636-9.
- \*Hasan UA, Bates E, Takeshita F, Biliato A, Accardi R, Bouvard V, Mansour M, Vincent I, Gissmann L, Iftner T, Sideri M, Stubenrauch F, Tommasino M (2007). TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. *J. Immunol.*, 178: 3186-97.
- \*Rollison DE, Pawlita M, Giuliano AR, Iannacone MR, Sondak VK, Messina JL, Cruse CW, Fenske NA, Glass LF, Kienstra M, Michael KM, Waterboer T, Gheit T, Tommasino M (2008). Measures of cutaneous human papillomavirus infection in normal tissues as biomarkers of HPV in corresponding non-melanoma skin cancers. *Int. J. Cancer*, 123: 2337-42.
- \*Sideri M, Cristoforoni P, Casadio C, Boveri S, Igdibashian S, Schmitt M, Gheit T, Tommasino M (2009). Distribution of human papillomavirus genotypes in invasive cervical cancer in Italy: A representative, single institution case series. *Vaccine*, 27: A30-A33.
- Aubin F, Gheit T, Prétet JL, Tommasino M, Mouglin C, Chosidow O (2009). Presence and persistence of human papillomavirus types 1, 2 and 4 on emery cardboards after scraping off plantar warts. *J. Am. Acad. Dermatol.* (in press).
- Cardone RA, Busco G, Bellizzi A, Cafarelli A, Monterisi S, Greco MR, Carratù P, Casavola V, Paradiso A, Tommasino M, Reshkin SJ (2008). HPV16 E7-dependent transformation activates NHE1 through a PKA-RhoA-induced inhibition of p38alpha. *PLoS One*, 3(10):e3529.
- Cazzaniga M, Gheit T, Casadio C, Khan N, Macis D, Valenti F, Miller MJ, Sylla BS, Akiba S, Bonanni B, Decensi A, Veronesi U, Tommasino M (2009). Analysis of the presence of cutaneous and mucosal papillomavirus types in ductal lavage fluid, milk and colostrum to evaluate its role in breast carcinogenesis. *Breast Cancer Res. Treat.*, 114:599-605.
- Cordano P, Gillan V, Bratlie S, Bouvard V, Banks L, Tommasino M, Campo MS (2008). The E6E7 oncoproteins of cutaneous human papillomavirus type 38 interfere with the interferon pathway. *Virology*, 377: 408-18.
- Dell'Oste V, Azzimonti B, Mondini M, De Andrea M, Borgogna C, Mesturini R, Accardi R, Tommasino M, Landolfo S, Dianzani U, Gariglio M (2008). Altered expression of UVB-induced cytokines in human papillomavirus (HPV)-immortalized epithelial cells. *J. Gen. Virol.*, 89: 2461-6.
- Dong W, Arpin C, Accardi R, Gissmann L, Sylla BS, Marvel J and Tommasino M (2008). Loss of p53 or p73 in human papillomavirus type 38 E6 and E7 transgenic mice partially restores the UV-activated cell cycle checkpoints. *Oncogene*, 27: 2923-8.
- Gabet AS, Accardi R, Bellopede A, Popp S, Boukamp P, Sylla BS, Londoño-Vallejo JA, Tommasino M (2008). Impairment of the telomere/telomerase system and genomic instability are associated with keratinocyte immortalization induced by the skin Human Papillomavirus type 38. *FASEB J.*, 22: 622-32.
- Galluccio M, Pochini L, Amelio L, Accardi R, Tommasino M, Indiveri C (2009). Over-expression in *E. coli* and purification of the human OCTN1 transport protein. *Protein Expr. Purif.* [Epub ahead of print]
- Gheit T, Vaccarella S, Schmitt M, Pawlita M, Franceschi S, Sankaranarayanan R, Sylla BS, Tommasino M, Gangane N (2009). Prevalence of human papillomavirus types in cervical and oral cancers in central India. *Vaccine*, 27: 636-9.
- Keita N, Clifford GM, Koulibaly M, Douno K, Kabba I, Haba M, Sylla BS, van Kemenade FJ, Snijders PJ, Meijer CF, Franceschi S (2009). HPV infection in women with and without cervical cancer in Conakry, Guinea. *Br. J. Cancer*, 101: 202-208.
- Lee K, Magalhaes I, Clavel C, Briolat J, Birembaut P, Tommasino M, Zehbe I (2008). Human papillomavirus 16 E6, L1, L2 and E2 gene variants in cervical lesion progression. *Virus Res.*, 131: 106-10.
- Massimi P, Thomas M, Bouvard V, Ruberto I, Campo S, Tommasino M, Banks L (2008). Comparative transforming potential of different Human Papillomaviruses associated with non-melanoma skin cancer. *Virology*, 371: 374-9.
- Rollison DE, Pawlita M, Giuliano AR, Iannacone MR, Sondak VK, Messina JL, Cruse CW, Fenske NA, Glass LF, Kienstra M, Michael KM, Waterboer T, Gheit T, Tommasino M (2008). Measures of cutaneous human papillomavirus infection in normal tissues as biomarkers of HPV in corresponding non-melanoma skin cancers. *Int. J. Cancer*, 123: 2337-42.
- Rubio I, Bolchi A, Moretto N, Canali E, Gissmann L, Tommasino M, Müller M, Ottonello S (2009). Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20—38) peptide displayed on bacterial thioredoxin. *Vaccine*, 27: 1949-56.
- Ruer JB, Pépin L, Gheit T, Vidal C, Kantelip B, Tommasino M, Prétet JL, Mouglin C, Aubin F (2009). Detection of alpha- and beta-human papillomavirus (HPV) in cutaneous melanoma: a matched and controlled study using specific multiplex PCR combined with DNA microarray primer extension. *Exp. Dermatol.* [Epub ahead of print]
- Sebastian S, Azzariti A, Accardi R, Conti D, Pilato B, LaCalamita R, Porcellini L, Simone GM, Tommasi S, Tommasino M, Paradiso A (2008). Validation of gefitinib effectiveness in a broad panel of head and neck squamous carcinoma cells. *Int. J. Mol. Med.*, 21: 809-17.

Sideri M, Cristoforoni P, Casadio C, Boveri S, Igdibashian S, Schmitt M, Gheit T, Tommasino M (2009). Distribution of human papillomavirus genotypes in invasive cervical cancer in Italy: A representative, single institution case series. *Vaccine*, 27: A30-A33.

Textor S, Dürst M, Jansen L, Accardi R, Tommasino M, Trunk MJ, Porgador A, Watzl C, Gissmann L, Cerwenka A (2008). Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer. *Int. J. Cancer*, 123: 2343-53.

Tommasino M, Accardi R, Hasan U (2008). Early genes of human papillomaviruses. In *Encyclopedia of Cancer*, Springer (in press)

Zehbe I, Richard C, DeCarlo C, Shai A, Lambert PF, Lichtig H, Tommasino M, Sherman L (2009). Human papillomavirus 16 E6 variants differ in their dysregulation of human keratinocyte differentiation and apoptosis. *Virology*, 383: 69-77.





# INFECTIONS AND CANCER EPIDEMIOLOGY GROUP (ICE)

## **Group Head**

Dr Silvia Franceschi

## **Scientists**

Dr Gary Clifford

Dr Hugo De Vuyst (November 2006–June 2009)

Mr Martyn Plummer

Dr Salvatore Vaccarella

## **Expertise Transfer Fellow**

Dr Robert Biggar (June 2009-October 2009)

## **Visiting Scientist**

Dr Christian Partensky (September 2009-February 2010)

Dr Julian Peto (from December 2009)

## **Special Services Agreement**

Ms Annie Arslan (June 2009-November 2009)

## **Data Managers**

Mr Didier Colin

Ms Sophie Pallardy (from April 2009)

Ms Vanessa Tenet (from August 2009)

## **Secretariat**

Ms Sylvie Nouveau

Ms Trudy Perdrix-Thoma (Group Secretary)

## **Postdoctoral fellows**

Dr Catherine de Martel (July 2008-December 2009)

Dr Bolormaa Dondog (September 2008-September 2010)

Dr Rebecca Howell-Jones (September 2009-August 2010)

Dr Ni Li (June 2009-September 2009)

Dr Syed Ahsan Raza (May 2009-September 2009)

## **Students**

Mr Jean-Damien Combes (May 2009–November 2009)

Mr Mauro Lise (September 2008-March 2010)

Ms Sheena Sullivan (June 2009-September 2009)

## HUMAN PAPILLOMAVIRUS (HPV)

The study of HPV, the necessary cause of cervical cancer, has been the main focus of the Infections and Cancer Epidemiology Group (ICE) in the last two years and has led to 25 published articles, as well as several in press, on related topics.


The successful introduction of vaccines against HPV, as well as HPV-based testing, presupposes accurate knowledge of the infection burden and type-specific distribution of HPV types in different parts of the world. In order to address this issue and fill knowledge gaps on this subject, ICE has carried out in the last two years new population-based HPV prevalence surveys among women with and without cervical cancer in six world areas (\*Bardin *et al.*, 2008; \*Dondog *et al.*, 2008; \*Keita *et al.*, 2009; \*Sherpa *et al.*, 2009) (Figure 1). HPV testing is also in progress for an additional study site in Iran.

The existence of populations in which HPV prevalence does not diminish in middle-aged women is one of the most important discoveries of the IARC HPV Prevalence Surveys (Figure 2).

Meta-analyses of women with and without cervical cancer, as well as cancers of the anogenital tract, have also been carried out or updated. This has resulted in publications showing that worldwide HPV16/18 prevalence in cervical cancer is indeed more similar than initially expected, lending further credence to the universal efficacy of the HPV vaccines currently available (\*Schiffman *et al.*, 2009). A meta-analysis on anogenital cancers further suggested that approximately 40% of vulvar, 70% of vaginal and 84% of anal carcinoma may be prevented by current HPV vaccines against HPV16/18 (\*De Vuyst *et al.*, 2009).

### INTERNATIONAL COLLABORATION ON CERVICAL CANCER

During this period, we have brought to fruition two collaborative manuscripts on the role of sexual behaviour in cervical cancer risk (\*International Collaboration of Epidemiological Studies of Cervical



\* Carried out in the last 2 years

Figure 1. Prevalence of cervical HPV DNA in sexually active women. IARC HPV Prevalence Surveys, 1995-2009.




Figure 2. Age-specific prevalence of high-risk HPV types in some less-developed countries. IARC HPV Prevalence Surveys (\*Franceschi *et al.*, 2006).

Cancer, 2009; \*Louie *et al.*, 2009). The risk of cervical cancer increased with lifetime number of sexual partners, as expected. We also highlighted, however, the association with early age at first sexual intercourse after careful adjustment for confounding factors. It is conceivable that age at first intercourse

is related to invasive cervical cancer risk through HPV acquisition. One possibility is that cervical cancer risk may increase with duration of HPV infection. It is likely that women who have earlier first sexual intercourse are also exposed to HPV earlier, and might have longer duration of infection.

## BAYESIAN MODELS APPLIED TO CANCER ETIOLOGY

A natural history model for infection and clearance of HPV infection in the ASCUS-LSIL Triage Study (ALTS) demonstrated that distinct HPV types act as independent agents with no impact on incidence or clearance of other types (\*Plummer *et al.*, 2007). Further investigation of the determinants of HPV persistence showed that, contrary to some recent claims, newly appearing infections clear equally well among older and younger women (\*Maucort-Boulch *et al.*, 2009). Therefore, for persistent infection old age is a proxy of "old age" of HPV infection (i.e. a poor prognostic factor).

## HUMAN IMMUNODEFICIENCY VIRUS/ ACQUIRED IMMUNE DEFICIENCY SYNDROME (HIV/AIDS)

Cancer risk in people with HIV/AIDS (PWA) is a subject of great importance to ICE now that PWA have improved survival as a result of highly active antiretroviral therapy (HAART). ICE has used record-linkage and cohort studies in Switzerland and Italy to achieve both an adequate study power for uncommon neoplasms (e.g. hepatocellular carcinoma, Hodgkin lymphoma) and accurate information on markers of immunity and use of HAART (10 publications in 2008–2009 and several in press). A second line of research has focused on the way HIV infection modifies the cancer potential of HPV infections in countries at very high-risk for both infections (i.e., Kenya and Uganda) (\*De Vuyst *et al.*, 2008).

Significantly elevated risks in PWA versus the general population were found for Hodgkin lymphoma, hepatocellular carcinoma, cancers of the cervix, anus, liver, lip, mouth and pharynx, trachea and lung, multiple myeloma and non-melanomatous skin cancer (\*Dal Maso *et al.*, 2009). The incidence of non-Hodgkin lymphoma and Kaposi sarcoma were shown to have greatly decreased in the HAART era (\*Polesel *et al.*, 2008; \*Franceschi *et al.*, 2008). HAART use was associated with a substantial weakening of the predictive value of CD4+ cell count, supporting the strong efficacy of HAART regardless of the degree of immune

impairment when treatment begins. The beneficial effect remained strong up to 10 years after HAART initiation (\*Polesel *et al.*, 2008; \*Franceschi *et al.*, 2008). Hodgkin lymphoma risk did not appear to be increasing in recent years among PWA using HAART, and the best predictive marker was low CD4+/CD8+ ratio (\*Clifford *et al.*, 2009). In a matched nested case-control study, lower CD4+ cell counts were shown for the first time to be significantly associated with hepatocellular carcinoma risk (\*Clifford *et al.*, 2008). Excess risks for cervical cancer among PWA are particularly high in Italy (\*Dal Maso *et al.*, 2009) as also reported in Spain. Although access to HAART is widespread, cervical screening among HIV-positive women needs to be improved.

## REFERENCE LIST

Bardin A, Vaccarella S, Clifford GM, Lissowska J, Rekosz M, Bobkiewicz P, Kupryjanczyk J, Krynicki R, Jonska-Gmyrek J, Danska-Bidzinska A, Snijders PJ, Meijer CJ, Zatonski W, Franceschi S (2008) Human papillomavirus infection in women with and without cervical cancer in Warsaw, Poland. *Eur J Cancer* 44: 557-564

Clifford GM, Rickenbach M, Lise M, Dal ML, Battagay M, Bohlius J, Boffi EI, Karrer U, Jundt G, Bordoni A, Ess S, Franceschi S (2009) Hodgkin lymphoma in the Swiss HIV Cohort Study. *Blood* 113: 5737-5742

Clifford GM, Rickenbach M, Polesel J, Dal Maso L, Steffen I, Ledergerber B, Rauch A, Probst-Hensch NM, Bouchardy C, Levi F, Franceschi S, Swiss HIV Cohort Study (2008) Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. *AIDS* 22: 2135-2141

Dal Maso L, Polesel J, Serraino D, Lise M, Piselli P, Falcini F, Russo A, Intrieri T, Vercelli M, Zambon P, Tagliabue G, Zanetti R, Federico M, Limina RM, Mangone L, De L, V, Stracci F, Ferretti S, Piffer S, Budroni M, Donato A, Giacomini A, Bellu F, Fusco M, Madeddu A, Vitarelli S, Tessandori R, Tumino R, Suligoi B, Franceschi S (2009) Pattern of cancer risk in persons with AIDS in Italy in the HAART era. *Br J Cancer* 100: 840-847

De Vuyst H, Clifford G. M., Li, N., and Franceschi S (2009) HPV infection in Europe. *Eur J Cancer* (In Press)

De Vuyst H, Gichangi PB, Estambale B, Njuguna E, Franceschi S, Temmerman M (2008) Human papillomavirus types in women with invasive cervical carcinoma by HIV status in Kenya. *Int J Cancer* 122: 244-246

Dondog B, Clifford GM, Vaccarella S, Waterboer T, Unurjargal D, Avirmed D, Enkhtuya S, Kommoss F, Wentzensen N, Snijders PJ, Meijer CJ, Franceschi S, Pawlita M (2008) Human papillomavirus infection in Ulaanbaatar, Mongolia: a population-based study. *Cancer Epidemiol Biomarkers Prev* 17: 1731-1738

Franceschi S, Dal Maso L, Rickenbach M, Polesel J, Hirschel B, Cavassini M, Bordoni A, Elzi L, Ess S, Jundt G, Mueller N, Clifford GM, the Swiss HIV Cohort Study (2008) Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. *Br J Cancer* 99: 800-804

Franceschi S, Herrero R, Clifford GM, Snijders PJ, Arslan A, Anh PT, Bosch FX, Ferreccio C, Hieu NT, Lazcano-Ponce E, Matos E, Molano M, Qiao YL, Rajkumar R, Ronco G, de Sanjose S, Shin HR, Sukvirach S, Thomas JO, Meijer CJ, Munoz N, and the IARC HPV Prevalence Surveys Study Group (2006) Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. *Int J Cancer* 119: 2677-2684

International Collaboration of Epidemiological Studies of Cervical Cancer (2009) Cervical carcinoma and sexual behavior: collaborative reanalysis of individual data on 15,461 women with cervical carcinoma and 29,164 women without cervical carcinoma from 21 epidemiological studies. *Cancer Epidemiol Biomarkers Prev* 18: 1060-1069

Keita N, Clifford GM, Koulibaly M, Douno K, Kabba I, Haba M, Sylla BS, van Kemenade FJ, Snijders PJ, Meijer CJ, Franceschi S (2009) HPV infection in women with and without cervical cancer in Conakry, Guinea. *Br J Cancer* 101: 202-208

Louie KS, de Sanjose S, Diaz M, Castellsague X, Herrero R, Meijer CJ, Shah K, Franceschi S, Munoz N, Bosch FX (2009) Early age at first sexual intercourse and early pregnancy are risk factors for cervical cancer in developing countries. *Br J Cancer* 100: 1191-1197

Maucort-Boulch, D., Plummer, M., Castle, P. E., Demuth, F, Safaeian, M., Wheeler, C., and Schiffman, M (2009) Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology. *Int J Cancer* In Press

Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM (2007) A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. *J Infect Dis* 195: 1582-1589

Polesel J, Clifford GM, Rickenbach M, Dal Maso L, Battagay M, Bouchardy C, Furrer H, Hasse B, Levi F, Probst-Hensch NM, Schmid P, Franceschi S, the Swiss HIV Cohort Study (2008) Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. *AIDS* 22: 301-306

Schiffman M, Clifford G, Buonaguro FM (2009) Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. *Infect Agent Cancer* 4: 8

Sherpa, ATL., Clifford, G., Vaccarella, S., Shrestha, S., Nygard, N., Karki, BS., Snijders, P., Meijer, C., and Franceschi, S (2009) Human papillomavirus infection in women with and without cervical cancer in Nepal. *Cancer Causes Control* (Submitted)

## PUBLICATIONS

Banura C, Franceschi S, van Doorn LJ, Arslan A, Kleter B, Wabwire-Mangen F, Mbidde EK, Quint W, Weiderpass E. Prevalence, incidence and clearance of human papillomavirus infection among young primiparous pregnant women in Kampala, Uganda. *Int J Cancer* 123: 2180-2187 (2008)

Banura C, Franceschi S, van Doorn LJ, Arslan A, Wabwire-Mangen F, Mbidde EK, Quint W, Weiderpass E. Infection with human papillomavirus and HIV among young women in Kampala, Uganda. *J Infect Dis* 197: 555-562 (2008)

Banura C, Franceschi S, van Doorn LJ, Wabwire-Mangen F, Mbidde EK, Weiderpass E. Detection of cervical human papillomavirus infection in filter paper samples: a comparative study. *J Med Microbiol* 57: 253-255 (2008)

Bardin A, Vaccarella S, Clifford GM, Lissowska J, Rekosz M, Bobkiewicz P, Kupryja\_czyk J, Krynicki R, Jonska-Gmyrek J, Danska-Bidzinska A, Snijders PJF, Meijer CJLM, Zatonski W, Franceschi S. Human papillomavirus infection in women with and without cervical cancer in Warsaw, Poland. *Eur J Cancer* 44: 557-564 (2008)

Bidoli E, Talamini R, Zucchetto A, Bosetti C, Negri E, Lenardon O, Dal Maso L, Polesel J, Montella M, Franceschi S, Serraino D, La Vecchia C. Dietary vitamins E and C and prostate cancer risk. *Acta Oncol* 18: 1-5 (2009)

Bidoli E, Talamini R, Zucchetto A, Polesel J, Bosetti C, Negri E, Maruzzi D, Montella M, Franceschi S, La Vecchia C. Macronutrients, fatty acids, cholesterol and renal cell cancer risk. *Int J Cancer* 122: 2586-2589 (2008)

Bosetti C, Gallus S, Talamini R, Montella M, Franceschi S, Negri E, La Vecchia C. Artificial sweeteners and the risk of gastric, pancreatic and endometrial cancers in Italy. *Cancer Epidemiol Biomarkers Prev* 18: 2235-2238 (2009)

Bosetti C, Gallus S, Peto R, Negri E, Talamini R, Tavani A, Franceschi S, La Vecchia C. Tobacco smoking, smoking cessation and cumulative risk of upper aerodigestive tract cancers. *Am J Epidemiol* 167: 468-473 (2008)

Bravi F, Scotti L, Bosetti C, Zucchetto A, Talamini R, Montella M, Greggi S, Pelucchi C, Negri E, Franceschi S, La Vecchia C. Food groups and endometrial cancer risk: a case-control study from Italy. *Am J Obstet Gynecol* 200: 293.e1-293.e7 (2009)

Canzian F, Franceschi S, Plummer M, van Doorn LJ, Lu Y, Gioia-Patricola L, Vivas J, Lopez G, Severson RK, Schwartz AG, Muñoz N, Kato I. Genetic polymorphisms in mediators of inflammation and gastric precancerous lesions. *Eur J Cancer Prev* 17: 178-183 (2008)

- Clifford GM, Franceschi S. Cancer risk in HIV-infected persons: influence of CD4+ count. *Future Oncol* 5: 669-678 (2009)
- Clifford GM, Rickenbach M, Lise M, Dal Maso L, Battegay M, Bohlius J, Boffi El Amari E, Karrer U, Jundt G, Bordoni A, Ess S, Franceschi S and the Swiss HIV Cohort Study. Hodgkin lymphoma in the Swiss HIV Cohort Study. *Blood* 113: 5737-5742 (2009)
- Clifford GM, Franceschi S. Members of the human papillomavirus type 18 family (alpha-7 species) share a common association with adenocarcinoma of the cervix [letter]. *Int J Cancer* 122: 1684-1685 (2008)
- Clifford GM, Rickenbach M, Polesel J, Dal Maso L, Steffen I, Ledergerber B, Rauch A, Probst-Hensch NM, Bouchardy C, Levi F, Franceschi S and the Swiss HIV Cohort Study. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. *AIDS* 22: 2135-2141 (2008)
- Collaborative Group on Epidemiological Studies of Ovarian Cancer (Franceschi S). Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,457 women with ovarian cancer and 87,303 controls. *Lancet* 371: 303-14 (2008)
- Dal Maso L, Bosetti C, La Vecchia C, Franceschi S. Risk factors for thyroid cancer: an epidemiological review focused on nutritional factors. *Cancer Causes Control* 20: 75-86 (2009)
- Dal Maso L, Polesel J, Serraino D, Lise M, Piselli P, Falcini F, Russo A, Intriari T, Vercelli M, Zambon P, Tagliabue G, Zanetti R, Federico M, Limina RM, Mangone L, De Lisi V, Stracci F, Ferretti S, Piffer S, Budroni M, Donato A, Giacomini A, Bellù F, Fusco M, Madeddu A, Vitarelli S, Tessandori R, Tumino R, Suligoi B, Franceschi S, for the Cancer and AIDS Registries Linkage (CARL) Study. Pattern of cancer risk in persons with AIDS in Italy in the HAART era. *Br J Cancer* 100: 840-847 (2009)
- Dal Maso L, Lise M, Zambon P, Crocetti E, Serraino D, Ricceri F, Vercelli M, De Lisi V, Tagliabue G, Federico M, Falcini F, Cassetti T, Donato A, Fusco M, Budroni M, Ferretti S, Tumino R, Piffer S, Bellù F, Mangone L, Giacomini A, Vitarelli S, Franceschi S. Incidence of primary liver cancer in Italy between 1988 and 2002: an age-period-cohort analysis. *Eur J Cancer* 44: 285-292 (2008)
- Dal Maso L, Zucchetto A, Talamini R, Serraino D, Stocco CF, Vercelli M, Falcini F, Franceschi S. Effect of obesity and other lifestyle factors on mortality in women with breast cancer [abstract]. *Ann Oncol* 19(Suppl9): 96-97 (2008)
- Dal Maso L, Zucchetto A, Talamini R, Serraino D, Stocco CF, Vercelli M, Falcini F, Franceschi S, for the Prospective Analysis of Case-control studies on Environmental factors and health (PACE) study group. Effect of obesity and other lifestyle factors on mortality in women with breast cancer. *Int J Cancer* 123: 2188-2194 (2008)
- de Martel C, Franceschi S. Infections and cancer: established associations and new hypotheses. *Crit Rev Oncol Hematol* 70: 183-194 (2009)
- de Martel C, Plummer M, Parsonnet J, van Doorn LJ, Franceschi S. Helicobacter species in cancers of the gallbladder and extra-hepatic biliary tract. *Br J Cancer* 100: 194-199 (2009)
- de Sanjosé S, Mbisa G, Perez-Alvarez S, Sukvirach S, Hieu NT, Shin HR, Pham Anh TH, Thomas J, Lazcano E, Matos E, Herrero R, Muñoz N, Molano M, Franceschi S, Whitby D. Geographic variation in the prevalence of Kaposi's sarcoma-associated herpesvirus and risk factors for transmission. *J Infect Dis* 199: 1449-1456 (2009)
- de Sanjosé S, Benavente Y, Vajdic CM, Engels EA, Morton LM, Bracci PM, Spinelli JJ, Zheng T, Zhang Y, Franceschi S, Talamini R, Holly EA, Grulich AE, Cerhan JR, Hartge P, Cozen W, Boffetta P, Brennan P, Maynadié M, Cocco P, Bosch R, Foretova L, Staines A, Becker N, Nieters A. Hepatitis C and non-Hodgkin lymphoma among 4,784 cases and 6,269 controls from the InterLymph Consortium. *J Clin Gastroenterol Hepatol* 6: 451-458 (2008)
- De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. *Int J Cancer* 124: 1626-1636 (2009)
- De Vuyst H, Gichangi P, Estambale B, Njuguna E, Franceschi S, Temmerman M. Human papillomavirus types in women with invasive cervical carcinoma by HIV status in Kenya. *Int J Cancer* 122: 244-246 (2008)
- De Vuyst H, Lillo F, Broutet N, Smith J. HIV, HPV and cervical dysplasia and cancer in the era of HAART. *Eur J Cancer Prev* 17: 545-54 (2008)
- Deandrea S, Talamini R, Foschi R, Montella M, Dal Maso L, Falcini F, La Vecchia C, Franceschi S, Negri E. Alcohol and breast cancer risk defined by estrogen and progesterone receptor status: a case-control study. *Cancer Epidemiol Biomarkers Prev* 17: 2025-2028 (2008)
- Diaz M, Kim JJ, Albero G, de Sanjosé S, Clifford GM, Bosch FX, Goldie SJ. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. *Br J Cancer* 99: 230-238 (2008)
- Dondog B, Clifford GM, Vaccarella S, Waterboer T, Unurjargal D, Avirmed D, Enkhuyaa S, Kommos F, Wentzensen N, Snijders PJF, Meijer CJLM, Franceschi S, Pawlita M. Human papillomavirus infection in Ulaanbaatar, Mongolia: a population-based study. *Cancer Epidemiol Biomarkers Prev* 17: 1731-1738 (2008)
- Edefonti V, Randi G, Decarli A, La Vecchia C, Bosetti C, Franceschi S, Dal Maso L, Ferraroni M. Clustering dietary habits and the risk of breast and ovarian cancers. *Ann Oncol* 20: 581-590 (2009)
- Edefonti V, Decarli A, La Vecchia C, Bosetti C, Randi G, Franceschi S, Dal Maso L, Ferraroni M. Nutrient dietary patterns and the risk of breast and ovarian cancers. *Int J Cancer* 122: 609-613 (2008)
- Franceschi S. Oral contraceptives and cervical cancer. *HPV Today* 17 (2009)
- Franceschi S, Dal Maso L, Zucchetto A, Talamini R, for the Prospective Analysis of Case-control studies on Environmental factors and health (PACE) study group. Alcohol consumption and survival after breast cancer [letter]. *Cancer Epidemiol Biomarkers Prev* 18: 1011-1012 (2009)
- Franceschi S, De Vuyst H. Human papillomavirus vaccines and anal carcinoma. *Curr Opin HIV/AIDS* 4: 57-63 (2009)
- Franceschi S. Infection: A Major Contributor to the Global Burden of Cancer. *Cancer Prevention Newsletter Issue no. 11* (2008)
- Franceschi S, Dal Maso L, Rickenbach M, Polesel J, Hirschel B, Cavassini M, Bordoni A, Elzi L, Ess S, Jundt G, Mueller N, Clifford GM and the Swiss HIV Cohort Study. Kaposi Sarcoma incidence in the Swiss HIV Cohort Study before and after Highly Active Antiretroviral Therapy. *Br J Cancer* 99: 800-804 (2008)
- Franceschi S, Clifford GM. Fraction of cervical neoplasias due to human papillomavirus 16 and 18 in vaccine trials [letter]. *Int J Cancer* 122: 719-720 (2008)
- Fusco M, Girardi E, Piselli P, Palombino R, Polesel J, Maione C, Scognamiglio P, Pisanti FA, Solmone M, Di Cicco P, Ippolito G, Franceschi S, Serraino D, for the Collaborating Study Group. Epidemiology of viral hepatitis infections in an area of southern Italy with high incidence rates of liver cancer. *Eur J Cancer* 44: 847-853 (2008)
- Garavello W, Lucenteforte E, Bossetti C, Talamini R, Levi F, Tavani A, Franceschi S, Negri E, La Vecchia C. Diet diversity and the risk of laryngeal cancer: a case-control study from Italy and Switzerland. *Oral Oncol* 45: 85-89 (2009)
- Garavello W, Foschi R, Talamini R, La Vecchia C, Rossi M, Dal Maso L, Tavani A, Levi F, Barzan L, Ramazzotti V, Franceschi S, Negri E. Family history and the risk of oral and pharyngeal cancer. *Int J Cancer* 122: 1827-1831 (2008)
- Garavello W, Giordano L, Bossetti C, Talamini R, Negri E, Tavani A, Maisonneuve P, Franceschi S, La Vecchia C. Diet diversity and risk of oral and pharyngeal cancer. *Eur J Nutr* 47: 280-284 (2008)

- Gheit T, Vaccarella S, Schmitt M, Pawlita M, Franceschi S, Sankaranarayanan R, Sylla B, Tommasino M, Gangane N. Prevalence of human papillomavirus types in cervical and oral cancers in central India. *Vaccine* 27: 636-639 (2009)
- Gonçalves MAG, Randi G, Arslan A, Lina Villa L, Donadi EA, Burattini MN, Franceschi S, Massad E. HPV type infection in different anogenital sites among HIV-positive Brazilian women. *Infect Agent Cancer* 3: 5 (2008)
- Hashibe M, Brennan P, Chuang SC, Boccia S, Castellsagué X, Chen C, Curado MP, Dal Maso L, Daudt AW, Fabianova E, Fernandez L, Wünsch-Filho V, Franceschi S, Hayes RB, Hererro R, Kelsey K, Koifman S, La Vecchia C, Lazarus P, Levi F, Lence JJ, Mates D, Matos E, Menezes A, McClean MD, Muscat J, Eluf-Neto J, Olshan AF, Purdue M, Rudnai P, Schwartz SM, Smith E, Sturgis EM, Szeszenia-Dabrowska N, Talamini R, Wei Q, Winn DM, Shangina O, Pilarska A, Zhang ZF, Ferro G, Berthiller J, Boffetta P. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the INHANCE consortium. *Cancer Epidemiol Biomarkers Prev* 18: 541-550 (2009)
- International Collaboration of Epidemiological Studies of Cervical Cancer (Franceschi S) Cervical carcinoma and sexual behavior: collaborative reanalysis of individual data on 15,461 women with cervical carcinoma and 29,164 women without cervical carcinoma from 21 epidemiological studies. *Cancer Epidemiol Biomarkers Prev* 18:1060-9 (2009)
- Keita N, Clifford GM, Koulibaly M, Douno K, Kabba I, Habba M, Sylla B, van Kemenade FJ, Snijders PJF, Meijer CJLM, Franceschi S. HPV infection in women with and without cancer in Conakry, Guinea. *Br J Cancer* 101: 202-208 (2009)
- Kita D, Ciernik IF, Vaccarella S, Franceschi S, Kleihues P, Lutolf UM, Ohgaki H. Age as predictive factor in glioblastomas: population-based study". *Neuroepidemiology* 33:17-22 (2009)
- Lambert R, Franceschi S. Carcinoma of the gallbladder. *World Gastroenterology News* 13(2) (2008)
- Li N, Shi JF, Franceschi S, Zhang WH, Dai M, Liu B, Zhang YZ, Li LK, Wu RF, De Vuyst H, Plummer M, Qiao YL, Clifford G. Different cervical cancer screening approaches in a Chinese multicentre study. *Br J Cancer* 100: 532-537 (2009)
- Lipworth L, Bender TJ, Rossi M, Bosetti C, Negri E, Talamini R, Giacosa A, Franceschi S, McLaughlin JK, La Vecchia C. Dietary vitamin D intake and cancers of the colon and rectum: a case-control study in Italy. *Nutr Cancer* 61: 70-75 (2009)
- Louie KS, de Sanjosé S, Diaz M, Castellsagué X, Herrero R, Meijer CJL, Shah K, Franceschi S, Muñoz N, Bosch FX, for the International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Early age at first sexual intercourse and early pregnancy are risk factors for cervical cancer in developing countries. *Br J Cancer* 100: 1191-1197 (2009)
- Lucenteforte E, Talamini R, Montella M, Dal Maso L, Pelucchi C, Franceschi S, La Vecchia C, Negri E. Family history of cancer and risk of endometrial cancer. *Eur J Cancer Prev* 18: 95-99 (2009)
- Lucenteforte E, Garavello W, Bosetti C, Talamini R, Zambon P, Franceschi S, Negri E, La Vecchia C. Diet Diversity and the risk of squamous cell esophageal cancer. *Int J Cancer* 123: 2397-2400 (2008)
- Lucenteforte E, Talamini R, Montella M, Dal Maso L, Tavani A, Deandrea S, Pelucchi C, Greggi S, Zucchetto A, Barbone F, Parpinel M, Franceschi S, La Vecchia C, Negri E. Macronutrients, fatty acids and cholesterol intake and endometrial cancer. *Ann Oncol* 19: 168-172 (2008)
- Maucort-Boulch D, Franceschi S, Plummer M. International correlation between human papillomavirus prevalence and cervical cancer incidence. *Cancer Epidemiol Biomarkers Prev* 17: 717-720 (2008)
- Montella M, Tramacere I, Tavani A, Gallus S, Crispo A, Talamini R, Dal Maso L, Ramazzotti V, Galeone C, Franceschi S, La Vecchia C. Coffee decaffeinated coffee, tea intake and risk of renal cell cancer. *Nutr Cancer* 61: 76-80 (2009)
- Nascimento MC, Akico de Souza V, Masami Sumita L, Freire W, Weiss HA, Sabino EC, Franceschi S, Pannuti CS, Mayaud P. Prevalence of, and risk factors for, Kaposi's sarcoma-associated herpesvirus (KHSV) infection among blood donors in Brazil: a multi-centre serosurvey. *J Med Virol* 80: 1202-1210 (2008)
- Nascimento MC, Mayaud P, Sabino EC, Luz Torres K, Franceschi S. Prevalence of hepatitis B and C serological markers among first-time blood donors in Brazil: A multi-centre serosurvey. *J Med Virol* 80: 53-57 (2008)
- Negri E, Boffetta P, Berthiller J, Castellsagué X, Curado MP, Dal Maso L, Daudt AW, Fabianova E, Fernandez L, Wünsch-Filho V, Franceschi S, Hayes RB, Herrero R, Koifman S, Lazarus P, Lence JJ, Levi F, Mates D, Matos E, Menezes A, Muscat J, Eluf-Neto J, Olshan AF, Rudnai P, Shangina O, Sturgis EM, Szeszenia-Dabrowska N, Talamini R, Wei Q, Winn DM, Zaridze D, Lissowska J, Zhang ZF, Ferro G, Brennan P, La Vecchia C, Hashibe M. Family history of cancer: pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. *Int J Cancer* 124: 394-401 (2009)
- Oh JK, Franceschi S, Kim BK, Kim JY, Ju YH, Hong EK, Chang YC, Rha SH, Kim HH, Kim JH, Kim CY, Shin HR. Prevalence of human papillomavirus and Chlamydia trachomatis infection among women attending cervical cancer screening in the Republic of Korea. *Eur J Cancer Prev* 18: 56-61 (2009)
- Oh JK, Ju YH, Franceschi S, Quint W, Shin HR. Acquisition of new infection and clearance of type-specific human papillomavirus infections in female students in Busan, South Korea: a follow-up study. *BMC Infect Dis* 8:13 (2008)
- Parkin DM, Almonte M, Bruni L, Clifford G, Curado MP, Piñeros M. Chapter 10: Burden & Trends of HPV prevalence, HPV-associated cancer and other diseases in Latin America and Caribbean. *Vaccine* 26(S11): L1-L15 (2008)
- Parkin DM, Louie K, Clifford G. Chapter 18: Burden & Trends of HPV prevalence, HPV-associated cancer and other diseases in the Asia-Pacific region. *Vaccine* 26(S12): M1-M16 (2008)
- Pelucchi C, Dal Maso L, Montella M, Parpinel M, Negri E, Talamini R, Giudice A, Franceschi S, La Vecchia C. Dietary intake of carotenoids and retinol and endometrial cancer risk in an Italian case-control study. *Cancer Causes Control* 19: 1209-1215 (2008)
- Pelucchi C, Galeone C, Montella M, Polesel J, Crispo A, Talamini R, Negri E, Ramazzotti V, Grimaldi M, Franceschi S, La Vecchia C. Alcohol consumption and renal cell cancer risk in two Italian case-control studies. *Ann Oncol* 19: 1003-1008 (2008)
- Plummer M. Penalized loss functions for Bayesian model comparison. *Biostatistics* 9: 523-539 (2008)
- Polesel J, Zucchetto A, Montella M, Dal Maso L, Crispo A, La Vecchia C, Serraino D, Franceschi S, Talamini R. The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. *Ann Oncol* 20: 353-357 (2009)
- Polesel J, Clifford GM, Rickenbach M, Dal Maso L, Battegay M, Bordoni A, Bouchardey C, Furrer H, Hasse B, Jundt G, Ledergerber B, Levi F, Probst-Hensch NM, Schmid P, Franceschi S, and the Swiss HIV Cohort Study. Non-Hodgkin lymphoma in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. *AIDS* 22: 301-306 (2008)
- Polesel J, Talamini R, La Vecchia C, Levi F, Barzan L, Serraino D, Franceschi S, Dal Maso L. Tobacco smoking and the risk of upper aero-digestive tract cancers: a reanalysis of case-control studies using spline models. *Int J Cancer* 122: 2398-2402 (2008)
- Purdue MP, Hashibe M, Berthiller J, La Vecchia C, Dal Maso L, Herrero R, Franceschi S, Castellsagué X, Wei Q, Sturgis EM, Morgenstern H, Zhang ZF, Levi F, Talamini R, Smith E, Muscat J, Lazarus P, Schwartz SM, Chen C, Eluf-Neto J, Wünsch-Filho V, Zaridze D, Koifman S, Curado MP, Benhamou S, Matos E, Szeszenia-Dabrowska N, Olshan AF, Lence J, Menezes A, Daudt AW, Mates IN, Pilarska A, Fabianova E, Rudnai P, Winn D, Ferro G, Brennan P, Boffetta P, Hayes RB. Type of alcoholic beverage

- and risk of head and neck cancer – a pooled analysis within the INHANCE consortium. *Am J Epidemiol* 169: 132-142 (2009)
- Randi G, Malvezzi M, Levi F, Ferlay J, Negri E, Franceschi S, La Vecchia C. Epidemiology of biliary tract cancers: an update. *Ann Oncol* 20: 146-159 (2009)
- Randi G, Ferraroni M, Talamini R, Garavello W, Deandrea S, Decarli A, Franceschi S, La Vecchia C. Glycemic index, glycemic load and thyroid cancer risk. *Ann Oncol* 19: 380-383 (2008)
- Rossi M, McLaughlin JK, Lagiou P, Bosetti C, Talamini R, Lipworth L, Giacosa A, Montella M, Franceschi S, La Vecchia C. Vitamin D intake and breast cancer risk: a case-control study in Italy. *Ann Oncol* 20: 374-378 (2009)
- Rossi M, Negri E, Bosetti C, Dal Maso L, Talamini R, Giacosa A, Montella M, Franceschi S, La Vecchia C. Mediterranean diet in relation to body mass index and waist-to-hip ratio. *Public Health Nutr* 11: 214-217 (2008)
- Rossi M, Negri E, Lagiou P, Talamini R, Dal Maso L, Montella M, Franceschi S, La Vecchia C. Flavonoids and ovarian cancer risk: a case-control study in Italy. *Int J Cancer* 123: 895-898 (2008)
- Shi JF, Qiao YL, Smith J, Dondog B, Bao YP, Dai M, Clifford G, Franceschi S. Chapter 22: Epidemiology and prevention of human papillomavirus and cervical cancer in China and Mongolia. *Vaccine* 26(S12): M53-M59 (2008)
- Talamini R, Polesel J, Spina M, Chimienti E, Serraino D, Zucchetto A, Zanet E, Franceschi S, Tirelli U. The impact of tobacco smoking and alcohol drinking on survival of patients with non-Hodgkin lymphoma. *Int J Cancer* 122: 1624-1629 (2008)
- Vaccarella S, Herrero R, Snijders PJF, Dai M, Thomas JO, Hieu NT, Ferreccio C, Matos E, Posso H, de Sanjosé S, Shin HR, Sukvirach S, Lazcano-Ponce E, Muñoz N, Meijer CJLM, Franceschi S, and the IARC HPV Prevalence Surveys Study Group. Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV prevalence surveys. *Int J Epidemiol* 37: 536-546 (2008)
- Wheeler CM, Franceschi S. EUROGIN 2007 roadmap. *Vaccine* 26: A28-A31 (2008)
- Zawlik I, Kita D, Vaccarella S, Mittelbronn M, Franceschi S, Ohgaki H. Common polymorphisms in the MDM2 and TP53 genes and the relationship between TP53 mutations and patient outcomes in glioblastomas. *Brain Pathol* 19: 188-194 (2009)
- Zawlik I, Vaccarella S, Kita D, Mittelbronn M, Franceschi S, Ohgaki H. Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: A population-based study. *Neuroepidemiology* 32: 21-29 (2009)
- Zucchetto A, Talamini R, Dal Maso L, Negri E, Polesel J, Ramazzotti V, Montella M, Canzonieri V, Serraino D, La Vecchia C, Franceschi S. Reproductive, menstrual, and other hormone-related factors and risk of renal cell cancer. *Int J Cancer* 123: 2213-2216 (2008)